Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cherian Sajan

Interventional Pain Medicine Winter Park, FL Medical Doctor

NPI 1174764153 CMS profile 98408

1693 Lee Rd, Suite B, Winter Park, FL 32789

Open in the dashboard

General payments

$12,833

564 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,977 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Cherian Sajan of Winter Park, FL is reported in the CMS Open Payments database as having received $12,833 across 564 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $11,977 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 78th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,015 36
2024 General $2,199 54
2023 General $1,342 41
2022 General $1,662 80
2021 General $3,415 135
2020 General $1,359 103
2019 General $1,841 115

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cherian Sajan
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Cherian Sajan were reported at $1,015. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Cherian Sajan Interventional Pain Medicine median Middle half National median
2019 $1,841 $684 $216–$2,079 $163
2020 $1,359 $382 $122–$1,109 $114
2021 $3,415 $552 $167–$1,554 $132
2022 $1,662 $605 $187–$1,924 $149
2023 $1,342 $671 $195–$1,915 $160
2024 $2,199 $684 $206–$1,837 $164
2025 $1,015 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $3,306 217 payments
  2. Boston Scientific Corporation $1,044 34 payments
  3. Curonix LLC $1,000 11 payments
  4. Stimwave Technologies Incorporated $751 8 payments
  5. Medtronic USA, Inc. $741 39 payments
  6. Nalu Medical, Inc. $665 8 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $650 32 payments
  8. Scilex Pharmaceuticals Inc. $640 40 payments
  9. IBSA Pharma Inc. $414 27 payments
  10. Vertos Medical, Inc. $401 9 payments
  11. Other $3,221 139 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,006 551 payments
  2. Travel and Lodging $1,731 11 payments
  3. Entertainment $75 1 payment
  4. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. Omnia $1,410 89 payments
  2. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $1,000 11 payments
  3. Senza $962 37 payments
  4. Senza Spinal Cord Stimulation System $784 89 payments
  5. Nalu Neurostimulation System $665 8 payments
  6. INTELLIS $532 23 payments
  7. RELISTOR $507 24 payments
  8. ZTLido $460 28 payments
  9. Licart $414 27 payments
  10. Freedom 4A Receiver Kit Channel A US w Receiver $383 2 payments
  11. Other $8,515 271 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

11,166

Median for Interventional Pain Management: 1,220

Drug cost

$386,761

Median for Interventional Pain Management: $39,344

Branded share of claims

65.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 2,853 $93,881
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 2,936 $69,577
Xtampza Er Oxycodone Myristate Brand 87 $42,696
Nucynta Tapentadol Hcl Brand 47 $36,456
Morphine Sulfate Er Morphine Sulfate Brand 889 $19,789
Pregabalin Generic 671 $18,400
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 157 $15,815
Belbuca Buprenorphine Hcl Brand 21 $13,663
Fentanyl Generic 155 $12,411
Morphine Sulfate Generic 511 $9,936

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$130,319

Of which drugs: $9,935

Medicare patients

215

Average age 72

Services billed

3,173

130 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 43%
Depression 40%
Diabetes 34%
Chronic kidney disease 34%
Atrial fibrillation 23%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ROXYBOND
  • PROTEGA PHARMACEUTIALS LLC $70
$70 — —
ZTLido
  • Scilex Pharmaceuticals Inc. $53
$53 — —
Qutenza
  • Averitas Pharma Inc. $53
$53 — —
Tirosint
  • IBSA Pharma Inc. $48
$48 — —
Licart
  • IBSA Pharma Inc. $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

564 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record